Richard H. Aldrich

Richard H. Aldrich is the co-founder and has served as a member of the Board of Directors and as Chairman of the Board of Directors since May 2006. Mr. Aldrich is a co-founder and has been a Partner at Longwood Fund, a life sciences venture capital firm, since December 2010. Prior to co-founding Longwood, Mr. Aldrich co-founded RA Capital Management LLC, a life sciences investment fund, in 2001, in which he remains an investor. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc., (acquired by GlaxoSmithKline in 2008), Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., Axial Therapeutics, and can Therapeutics. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich also serves on the board of directors of a number of private biotechnology companies including Axial, Renovia, Sitryx Therapeutics, and Colorescience. Mr. Aldrich received his B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College. They believe Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life science companies, and his familiarity with the business as a co-founder of the company make him be a key contributor to the Board.